LIVE
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant comm. Track Wockhardt Limited's live NSE:WOCKPHARMA share price ₹1,963.10 (+0.28%), market cap ₹₹319B, P/E 149.5. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for WOCKPHARMA — real-time NSE India stock intelligence.
Open
₹1,967.00
High
₹1,980.00
Low
₹1,941.00
Prev. Close
₹1,957.70
52W High
₹2,422.30
52W Low
₹1,086.70
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant comm
Key Takeaway
Wockhardt Limited is rated none with a P/E of 149.5x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is Wockhardt Limited fairly valued right now?
Because a P/E of 149.5x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting Wockhardt Limited
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
965 Cr
Revenue
166 Cr
Net Profit
4%
ROE
0%
ROCE
13.13
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 2,646 | 2,789 | 2,915 | 3,317 | 3,334 |
| Net Profit | -559 | -463 | -47 | 213 | 110 |
| ROE (%) | — | — | — | 4.0% | 4.0% |
| EPS (₹) | — | — | — | 13.13 | 13.13 |
| Debt/Equity | — | — | — | 42.3 | 42.3 |